Cis-urocanic acid

N/A

Report date: 2026/03/09 20:02:04

Base Information

Drug NameCis-urocanic acid
Drug Alias NameProtoCureUCA-001UCA-002Cis-UCA
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin-6 inhibitorsc-Jun N-terminal kinase inhibitorsInterleukin-8 inhibitors
TargetsInterleukin-6c-Jun N-terminal kinaseInterleukin-8
Therapy Area/IndicationsDermatitis, AtopicDry Eye SyndromesXerophthalmia +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFinland
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesHerantis Pharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLaurantis Pharma LtdBiocis Pharma LtdHerantis Pharma Plc.
Active IndicationsN/A
Inactive IndicationsDermatitis, AtopicDry Eye SyndromesXerophthalmia +[4] 

Other Information

ATC CodeN/A
Related LinksN/A